Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia

Emerging Microbes and Infections

Volumn 9, Issue 1, 2020, Pages 727-732

  Lin, Ling ^a   Lu, Lianfeng ^a   Cao, Wei ^a   Li, Taisheng ^a,b,c  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c Tsinghua University   (China)

Author keywords

anticoagulation; COVID 19; IVIg; pathogenesis; SARS CoV 2

Indexed keywords

CORONAVIRUS DISEASE 2019; HUMAN; IMMUNITY; MIDDLE EAST RESPIRATORY SYNDROME; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS PNEUMONIA; ANIMAL; B LYMPHOCYTE; BETACORONAVIRUS; BLOOD; CORONAVIRUS INFECTION; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); METABOLISM; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; PANDEMIC; PATHOGENICITY; SARS CORONAVIRUS; T LYMPHOCYTE; VIROLOGY;

ANTICOAGULANT AGENT; CYTOKINE; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR; LOW MOLECULAR WEIGHT HEPARIN; VIRUS ANTIBODY;

ANIMALS; ANTIBODIES, VIRAL; ANTICOAGULANTS; B-LYMPHOCYTES; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; CYTOKINES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMICS; PNEUMONIA, VIRAL; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; T-LYMPHOCYTES;

EID: 85082635131     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1080/22221751.2020.1746199     Document Type: Review

References (43)

1. Zhong N, Zheng B, Li Y, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet. 2003;362(9393):1353–1358. doi: 10.1016/S0140-6736(03)14630-2
2. World Health Organization: health topics [Internet]. WHO. [cited 2020 Feb 26]. Available from: http://www.emro.who.int/health-topics/
3. World Health Organization: emergencies[Internet] WHO. [updated 2020 Feb 25, cited 2020 Feb 26]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200225-sitrep-36-covid-19.pdf?sfvrsn=2791b4e0_2
4. Yu F, Du L, Ojcius DM, et al. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020;undefined:undefined.
5. National Health Commission: Diagnosis and treatment of pneumonia infected by novel coronavirus (trial Fifth Edition) CHINA. [updated 2020 Feb 05, cited 2020 Feb 26] Available from: http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml
6. Taisheng L, Zhifeng Q, Linqi Z, et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis. 2004;189(4):648–651. doi: 10.1086/381535
7. Ko JH, Park GE, Lee JY, et al. Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients. J Infect. 2016;73:468–475. doi: 10.1016/j.jinf.2016.08.005
8. Mohn KG, Cox RJ, Tunheim G, et al. Immune responses in acute and convalescent patients with mild, moderate and severe disease during the 2009 influenza pandemic in Norway. PLoS One. 2015;10(11):e0143281. doi: 10.1371/journal.pone.0143281
9. Liu Z Y, Li T S, Wang Z, et al. [Clinical features and therapy of 106 cases of severe acute respiratory syndrome]. Chinese J Intern Med. 2003;06:16–20. Chinese.
10. Li TS, Qiu ZF, Han Y, et al. [The alterations of T cell subsets of severe acute respiratory syndrome during acute phase]. Chinese J Lab Med. 2003;05:40–42. Chinese.
11. Xie J, Fan HW, Li TS, et al. [Dynamic changes of T lymphocyte subsets in the long-term follow-up of severe acute respiratory syndrome patients]. Chinese Acad Med Sci. 2006;28(2):253–255. Chinese.
12. Gang L, Chen MJ, Chen W, et al. [Variation in the titer of the specific IgG antibody in patients with SARS]. J Trop Med. 2003;03:283–285. Chinese.
13. Cao Z, Liu L, Du L, et al. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J. 2010;7(1):299. doi: 10.1186/1743-422X-7-299
14. Stockman LJ, Bellamy R, Garner P., SARS: Systematic review of treatment effects. PLoS Med. 2006;3(9):e343. doi: 10.1371/journal.pmed.0030343
15. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820. doi: 10.1056/NEJMoa1211721
16. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254. doi: 10.1038/nature12005
17. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454. doi: 10.1038/nature02145
18. Min CK, Cheon S, Ha NY, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016;6:25359. doi: 10.1038/srep25359
19. Zumla A, Hui DS, Perlman S., Middle East respiratory syndrome. Lancet. 2014;40(7):995–1007.
20. Saad M, Omrani AS, Baig K, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis. 2014;29:301–306. doi: 10.1016/j.ijid.2014.09.003
21. Alosaimi B, Hamed ME, Naeem A, et al. MERS-CoV infection is associated with downregulation of genes encoding Th1 and Th2 cytokines/chemokines and elevated inflammatory innate immune response in the lower respiratory tract. Cytokine. 2020;126:154895. doi: 10.1016/j.cyto.2019.154895
22. Shin HS, Kim Y, Kim G, et al. Immune responses to Middle East respiratory syndrome coronavirus during the acute and convalescent phases of human infection. Clin Infect Dis. 2019;68:984–992. doi: 10.1093/cid/ciy595
23. Wen DG, Pun MCK, Lin CZ, et al. Characteristics of traveler with Middle East respiratory syndrome, China, 2015. Emerg Infect Dis. 2015;21(12):2278–2280. doi: 10.3201/eid2112.151232
24. Stohlman SA, Bergmann CC, Veen RCVD, et al. Mouse hepatitis virus-specific cytotoxic T lymphocytes protect from lethal infection without eliminating virus from the central nervous system. J Virol. 1995;69(2):684–694. doi: 10.1128/JVI.69.2.684-694.1995
25. Zhao J, Alshukairi AN, Baharoon S A, et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Imm. 2017;2(14). undefined.
26. Bautista E, Chotpitayasunondh T, Gao ZC, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362(18):1708–1719. doi: 10.1056/NEJMra1000449
27. World Health Organization: newsroom [Internet]. WHO. [cited 2020 Feb 26]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).
28. Bermejo-Martin JF, Lejarazu ROD, Pumarola T, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care. 2009;13(6):R201. doi: 10.1186/cc8208
29. Wilkinson TM, Li CK, Chui CS, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012;18(2):274–280. doi:10.1038/nm.2612.
30. Geng TR, Han Y, Li TS, et al. [Characteristics and prognostic value of peripheral blood T lymphocyte subsets in patients with severe influenza]. Chinese J Inter Med. 2020;59(3). undefined. Chinese.
31. Juarez-Reyes A, Noyola DE, Monsivais-Urenda A, et al. Influenza virus infection but not H1N1 influenza virus immunization is associated with changes in peripheral blood NK cell subset levels. Clin Vaccine Immunol. 2013;20(8):1291–1297. doi: 10.1128/CVI.00194-13
32. Shieh WJ, Blau DM, Denison AM, et al. 2010 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol. 2010;177(1):166–175. doi: 10.2353/ajpath.2010.100115
33. de Wit E, Rasmussen AL, Falzarano D, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A. 2013;110(41):16598–16603. doi: 10.1073/pnas.1310744110
34. Munster VJ, de Wit E, van den Brand JM, et al. Pathogenesis and transmission of Swine-Origin 2009 A(H1N1) influenza virus in Ferrets. Science. 2009;325(5939):481–483. doi: 10.1126/science.1177127
35. Mcauliffe J, Vogel L, Roberts A, et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology. 2004;330(1):8–15. doi: 10.1016/j.virol.2004.09.030
36. Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS[J]. J Exp Med. 2005;202(3):415–424. doi: 10.1084/jem.20050828
37. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020;undefined:undefined. doi:10.1056/NEJMoa2002032.
38. Dan H, Maureen G, Richard B, et al. Quantitative mRNA expression pro¢ling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS. 2002;undefined:undefined. doi:undefined.
39. Letko M, Marzi A, Munster V., Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;undefined:undefined. doi:10.1038/s41564-020-0688-y.
40. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;undefined:undefined.
41. Wan SX, Yi QJ, Fan SB, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020;undefined:undefined, doi:10.1101/2020.02.10.20021832.
42. Liu Q, Zhou YH, Yang ZQ., The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016;13(1):3–10. doi: 10.1038/cmi.2015.74
43. Ho J, Wu A, Lam B, et al. Pentaglobin in steroid-resistant severe acute respiratory syndrome. Int J Tuberc Lung Dis. 2004;8(10):1173–1179.